UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 16, 1996
-------------
CORTEX PHARMACEUTICALS, INC.
------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-17951 33-0303583
------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No)
15241 Barranca Parkway, Irvine, California 92718
------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (714) 727-3157
Not Applicable
------------------------------------------------------------------
(Former name or former address, if changed since last report)
Page 1 of 12
Exhibit Index on Page 4
ITEM 5. OTHER EVENTS
On May 16, 1996, Cortex Pharmaceuticals, Inc. (the "Company") announced
the appointment of Vincent F. Simmon, Ph.D., 52 as President and Chief
Executive Officer and member of the Board of Directors of the Company,
effective immediately.
ITEM 6. EXHIBITS
Exhibits:
10.56 Employment Agreement dated May 15, 1996, between
Cortex Pharmaceuticals, Inc. and Vincent F. Simmon, Ph.D.
21 Press Release dated May 16, 1996.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CORTEX PHARMACEUTICALS, INC.
Date: June 3, 1996 By: /s/ D. Scott Hagen
----------------------------------------------
D. Scott Hagen
Vice President and Chief Financial Officer
EXHIBIT INDEX
Exhibits Description
-------- -----------
10.56 Employment Agreement dated May 15, 1996, between
Cortex Pharmaceuticals, Inc. and Vincent F.
Simmon, Ph.D.
21 Press release dated
May 16, 1996